Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-F9) - Purified No Carrier Protein

Referentie LT7005-500

Formaat : 500ug

Merk : Leinco Technologies


AntiSARSCoV2 Nucleocapsid (N) (Clone NP1F9) – Purified No Carrier Protein

Product No.: LT7005

Product No.LT7005
Clone
NP1F9
Target
SARSCoV2 Nucleocapsid (N)
Product Type
Recombinant Monoclonal Antibody
Alternate Names
COV2NP1E9, SARSCoV2 Nucleocapsid, SARSCoV2 Nucleoprotein, Protein N, SARSCoV N Protein
Isotype
Human IgG1
Applications
ELISA

Data

AntiSARSCoV2 N (Clone NP1F9) Data Image

Antibody Details

Product Details

Reactive Species
SARSCoV2
Virus
Host Species
Mouse
Expression Host
HEK293 Cells
Immunogen
SARSCoV2 Nucleocapsid (N) Protein
Product Concentration
≥1.0 mg/ml
Purity
≥90% monomer by analytical SEC and SDSPage
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multistep process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
This antibody may be stored sterile as received at 28°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ 70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Ships Overnight on Blue Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
AntiSARSCoV2 Nucleocapsid, clone NP1F9, specifically targets an epitope on the SARSCoV2 nucleocapsid protein.
Background
Severe acute respiratory syndrome coronavirus 2 (SARSCoV2), the causative agent of coronavirus disease 2019 (COVID19), is an enveloped, singlestranded, positivesense RNA virus that belongs to the Coronaviridae family 1. The SARSCoV2 genome, which shares 79.6% identity with SARSCoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) 2. The N protein is 46 kDa and consists of two highly conserved structural domains, the Nterminal domain (NTD) and Cterminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and selfoligomerization, respectively 3, 4. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex 5. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways 6, 7. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARSCoV N protein 8. It is also immunogenic, and antibodies 8,9 and memory T cells 10, 11 targeting the N protein are present in the sera of convalescent COVID19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARSCoV2 12. The N protein also contributes to immune evasion by antagonizing antiviral RNAi 13, suggesting its potential value as a targeted therapeutic.
Antigen Distribution
The nucleocapsid protein is expressed in the internal nucleocapsid of SARSCoV2.
NCBI Gene Bank ID
Research Area
COVID19
.
Infectious Disease
.
Seasonal and Respiratory Infections
.
Viral
.
IVD Raw Material

References & Citations

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):5972. 2006.
5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):1384813855. 2005.
6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397405. 2008.
7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):1027610288. 2010.
8. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(45):206211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 14. 2020.